CPIX CUMBERLAND PHARMACEUTICALS INC
Pharmaceutical Preparations · Nasdaq · SEC CIK 1087294 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY10.7%
TTM net income YoY2,167.1%
TTM EPS YoY1,962.5%
Revenue 3-yr CAGR-13.9%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-38.2%
Net margin273.7%
FCF margin-3.9%
EBITDA margin-33.6%
Returns
ROE139.5%
ROA76.6%
ROIC (approx.)-532.4%
Asset turnover0.28x
Leverage & solvency
Liabilities / assets36.6%
Debt / equity0.00x
Current ratio3.05x
Interest coverage-47.02x
Cash quality & payout
Operating cash flow / net income-0.01x
Accruals ratio77.6%
Payout ratio—
Capex / revenue0.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2025Q12026-03-31 | 2025Q42025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q42024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $2.16M | $166,458 | $9.13M | $13.68M | $171,821 | $380,797 | $11.71M | $10.44M |
| Cost of revenue | — | — | $1.93M | $2.24M | $988,760 | $2.01M | $1.43M | $1.98M |
| Gross profit | — | — | $7.20M | $11.44M | -$816,939 | -$1.63M | $10.29M | $8.46M |
| R&D expense | $841,162 | $772,162 | $1.46M | $1.55M | $646,473 | $837,401 | $1.30M | $1.29M |
| SG&A expense | $2.18M | $2.55M | $2.55M | $4.04M | $2.38M | $2.66M | $2.46M | $3.33M |
| Operating income | -$1.94M | -$3.16M | -$3.13M | -$1.37M | -$2.86M | -$3.12M | $1.29M | -$1.84M |
| Interest expense | $4,604 | $724 | $85,839 | $112,942 | $29 | $471 | $163,802 | $223,261 |
| Pretax income | -$1.12M | -$3.10M | -$3.14M | -$1.39M | -$2.72M | -$2.99M | $1.25M | -$1.96M |
| Income tax | $3,871 | $3,870 | $3,871 | $23,245 | $5,670 | $5,671 | $5,670 | -$56,996 |
| Net income | $77.78M | -$4.28M | -$3.29M | -$1.41M | -$1.94M | -$740,740 | $1.26M | -$1.90M |
| EBITDA | -$1.91M | -$4.37M | -$1.85M | -$329,307 | -$2.83M | -$2.09M | $2.32M | -$345,645 |
| EPS (basic) | 5.19 | -0.29 | -0.22 | -0.09 | -0.13 | -0.05 | 0.08 | -0.14 |
| EPS (diluted) | 5.07 | -0.29 | -0.22 | -0.09 | -0.13 | -0.05 | 0.08 | -0.14 |
| Weighted avg. shares (diluted) | 15.34M | 14.98M | 14.96M | — | 14.96M | 14.96M | 15.26M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $80.58M | $3.86M | $11.01M | $11.44M | $15.20M | $16.09M | $15.11M | $17.96M |
| Receivables | $2.13M | $13.42M | $14.26M | $16.94M | $10.43M | $10.32M | $10.49M | $11.70M |
| Inventory | $29,935 | $29,935 | $5.45M | $29,935 | $2.93M | $3.22M | $4.10M | $4.00M |
| Current assets | $104.56M | $33.64M | $32.79M | $37.06M | $29.94M | $31.21M | $31.88M | $36.45M |
| PP&E, net | $232,154 | $248,808 | $237,375 | $264,724 | $293,375 | $297,793 | $298,740 | $277,365 |
| Goodwill | — | — | $914,000 | $914,000 | $914,000 | $914,000 | $914,000 | $914,000 |
| Intangibles | $35,471 | $43,804 | $12.79M | $53,621 | $15.01M | $15.99M | $16.99M | $17.97M |
| Total assets | $113.78M | $62.88M | $71.00M | $76.82M | $65.90M | $67.91M | $69.94M | $75.58M |
| Current liabilities | $34.33M | $35.19M | $34.49M | $36.74M | $24.31M | $23.97M | $25.52M | $31.62M |
| Short-term debt | — | — | — | $0 | — | — | — | $5.10M |
| Total liabilities | $41.60M | $45.77M | $49.69M | $52.28M | $40.10M | $40.23M | $41.60M | $53.04M |
| Shareholders' equity | $72.51M | $17.44M | $21.64M | $24.88M | $26.12M | $27.99M | $28.66M | $22.85M |
| Shares outstanding | 14.99M | 14.98M | 14.98M | 14.96M | 14.96M | 14.96M | 14.96M | 13.95M |
| Cash flow statement | ||||||||
| Operating cash flow | -$1.50M | $168,740 | $387,025 | $3,024 | $187,179 | $843,801 | $3.90M | $1.90M |
| Capital expenditure | $9,812 | $38,283 | $0 | -$1 | $23,788 | $26,486 | $47,630 | $2,283 |
| Free cash flow | -$1.51M | $130,457 | $387,025 | $3,025 | $163,391 | $817,315 | $3.85M | $1.90M |
| Investing cash flow | $100.08M | -$1.93M | -$61,173 | -$3.07M | -$690,837 | $285,864 | -$1.23M | -$26,809 |
| Financing cash flow | -$21.87M | -$5.39M | -$763,300 | -$681,738 | -$386,879 | -$150,797 | -$5.53M | -$1.38M |
| Depreciation & amortization | $30,304 | -$1.20M | $1.28M | $1.04M | $21,555 | $1.03M | $1.03M | $1.50M |
| Stock-based compensation | $8,083 | $77,866 | $106,842 | $172,160 | $81,262 | $80,686 | $74,212 | $74,812 |
| Share buybacks | $257,819 | $0 | $61,001 | $0 | $10,439 | $7,171 | $245,868 | $98,383 |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.